Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to show an improvement in overall survival in a lung cancer trial.

Knee, back, and hip pain related to osteoarthritis (OA) can make moving your body uncomfortable. But choosing the right running or walking shoe can make a difference. Healthcare professionals ...

“These fatty acids, like oleic acid, help lock moisture into your skin, keeping it hydrated,” says Bowles. “As mentioned, it also contains vitamins A and E, which can potentially help with ...